To the full analysis
IDEXX Laboratories stock: growth
IDXXIDEXX Laboratories reported $4.3B in revenue for fiscal 2025, up 10.4% on the prior year, up 9.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
9.7%
per year from 2006 to 2025, per share 12.4%
Earnings (Annual rate)
13.6%
per year from 2006 to 2025, per share 16.3%
Free cash flow (Annual rate)
19%
per year from 2006 to 2025, per share 21.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 9.7% | 10.4% | 9.7% |
| Revenue per share | 11.1% | 12.0% | 12.4% |
| Earnings | 12.7% | 18.6% | 13.6% |
| Earnings per share | 14.1% | 20.3% | 16.3% |
| Free cash flow | 14.3% | 23.0% | 19.0% |
| Free cash flow per share | 15.7% | 24.7% | 21.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $739.12M | $93.68M | $38.47M |
| 2007 | $922.56M | $94.01M | $68.88M |
| 2008 | $1.02B | $116.17M | $53.37M |
| 2009 | $1.03B | $122.23M | $115.88M |
| 2010 | $1.1B | $141.28M | $139.53M |
| 2011 | $1.22B | $161.79M | $120.48M |
| 2012 | $1.29B | $178.27M | $161.23M |
| 2013 | $1.38B | $187.8M | $167.36M |
| 2014 | $1.49B | $181.91M | $175.15M |
| 2015 | $1.6B | $192.08M | $133.44M |
| 2016 | $1.78B | $222.05M | $269.78M |
| 2017 | $1.97B | $263.14M | $296.57M |
| 2018 | $2.21B | $377.03M | $277.15M |
| 2019 | $2.41B | $427.72M | $303.93M |
| 2020 | $2.71B | $581.78M | $540.44M |
| 2021 | $3.22B | $744.85M | $636M |
| 2022 | $3.37B | $679.09M | $394.15M |
| 2023 | $3.66B | $845.04M | $772.88M |
| 2024 | $3.9B | $887.87M | $798.08M |
| 2025 | $4.3B | $1.06B | $1.05B |
Revenue by segment
How IDEXX Laboratories, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Product59%
- Service41%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| Product | $2.09B | $2.25B | $2.54B | 59% |
| Service | $1.57B | $1.65B | $1.76B | 41% |
| Total revenue | $3.66B | $3.9B | $4.3B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2022)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.